Mepsevii
Mepsevii ingredients
| Active ingredient | Strength |
|---|---|
| Vestronidase Alfa | 2 mg/mL |
What Mepsevii is used for
The FDA lists the approved uses on the official label (below). In the EU, vestronidase alfa is approved as Mepsevii for:
Mepsevii is indicated for the treatment of non-neurological manifestations of Mucopolysaccharidosis VII (MPS VII; Sly syndrome).
EU wording from the European Medicines Agency; US approved uses can differ.
Key facts
- Brand
- Mepsevii
- Generic name
- Vestronidase alfa
- Made by
- Ultragenyx Pharmaceutical Inc.
- Forms
- Injection
- Given
- Intravenous
- Drug class
- Lysosomal beta Glucuronidase
- FDA approval
- Biologic licence (BLA) BLA761047
- On the US market since
- 2017
Official information
- MedlinePlus drug information (search for Vestronidase alfa)
Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.
Common questions
What is Mepsevii?
Mepsevii (Vestronidase alfa) is a specialist medicine made by Ultragenyx Pharmaceutical Inc., approved by the US FDA.
What are the ingredients of Mepsevii?
Mepsevii contains Vestronidase Alfa (2 mg/mL).
Is Mepsevii approved in Europe?
The same active substance is approved in the EU as Mepsevii.
From the FDA National Drug Code directory (open.fda.gov, public domain) and the European Medicines Agency medicines list. Page made 5 November 2026 by Satya Babu.
← All specialty medicines, USA